Refereed review article in scientific journal (A2)
Decorin-mediated oncosuppression – a potential future adjuvant therapy for human epithelial cancers
List of Authors: Annele Orvokki Sainio, Hannu Tapio Järveläinen
Publisher: British Pharmacological Society
Publication year: 2019
Journal: British Journal of Pharmacology
Journal acronym: Br J Pharmacol
Volume number: 176
Issue number: 1
Start page: 5
End page: 15
Number of pages: 11
ISSN: 0007-1188
eISSN: 1476-5381
DOI: http://dx.doi.org/10.1111/bph.14180
URL: https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bph.14180
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/31133576
Currently,
the multifaceted role of the extracellular matrix (ECM) in tumorigenesis has
been realized. One ECM macromolecule exhibiting potent oncosuppressive actions
in tumorigenesis is decorin, the prototype of the small leucine-rich
proteoglycan gene family. The actions of decorin include its capability to
function as an endogenous pan-receptor tyrosine kinase inhibitor, a regulator
of both autophagy and mitophagy, as well as a modulator of the immune system. In
this review, we will discuss these topics in more detail. We will also give a
summary of preclinical studies exploring the value of decorin-mediated
oncosuppression as a potential future adjuvant therapy for epithelial cancers.
Downloadable publication This is an electronic reprint of the original article. |